KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Other Non-Current Assets (2019 - 2025)

Arbutus Biopharma (ABUS) has disclosed Other Non-Current Assets for 7 consecutive years, with $130000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 282.35% to $130000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $130000.0 through Dec 2025, up 282.35% year-over-year, with the annual reading at $130000.0 for FY2025, 282.35% up from the prior year.
  • Other Non-Current Assets hit $130000.0 in Q4 2025 for Arbutus Biopharma, down from $131000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $190000.0 in Q1 2022 to a low of $3000.0 in Q3 2023.
  • Historically, Other Non-Current Assets has averaged $92166.7 across 5 years, with a median of $82500.0 in 2022.
  • Biggest five-year swings in Other Non-Current Assets: crashed 98.2% in 2023 and later surged 282.35% in 2025.
  • Year by year, Other Non-Current Assets stood at $61000.0 in 2021, then soared by 68.85% to $103000.0 in 2022, then plummeted by 97.09% to $3000.0 in 2023, then surged by 1033.33% to $34000.0 in 2024, then soared by 282.35% to $130000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for ABUS at $130000.0 in Q4 2025, $131000.0 in Q3 2025, and $34000.0 in Q1 2025.